Current Report Filing (8-k)
19 February 2020 - 10:37PM
Edgar (US Regulatory)
0001739104
false
0001739104
2020-02-18
2020-02-19
0001739104
us-gaap:CommonStockMember
2020-02-18
2020-02-19
0001739104
elan:TangiblePercentEquityUnitsMember
2020-02-18
2020-02-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): February 19, 2020
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
Indiana
|
|
001-38661
|
|
82-5497352
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
2500 Innovation Way
Greenfield, Indiana
(Address
of principal executive offices)
|
|
46140
(Zip
Code)
|
Registrant’s telephone number, including
area code: (877) 352-6261
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class:
|
Trading
Symbol(s)
|
Name
of each exchange on which registered:
|
Common Stock, no par value
|
ELAN
|
New York Stock Exchange
|
5.00% Tangible Equity Units
|
ELAT
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operation and Financial Condition.
|
Attached as Exhibit 99.1 and incorporated
by reference into this Item 2.02 is a copy of the press release, dated February 19, 2020, announcing the results of operations
for the fourth quarter and year ended December 31, 2019, for Elanco Animal Health Incorporated.
The information in this Item 2.02,
including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that
Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities
Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
Elanco Animal Health Incorporated
|
|
|
|
|
|
|
Date: February 19, 2020
|
By:
|
/s/ Michael-Bryant Hicks
|
|
|
Name: Michael-Bryant Hicks
|
|
|
Title: Executive Vice President, General Counsel and Corporate Secretary
|
Elanco Animal Health (NYSE:ELAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elanco Animal Health (NYSE:ELAT)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Elanco Animal Health Incorporated (New York Stock Exchange): 0 recent articles
More Elanco Animal Health Inc News Articles